Breaking Stories

Albert Labs announces chairs for its clinical and scientific advisory boards

Albert Labs has announced the chairs for its clinical and scientific advisory boards. 

In a statement, the private psychedelic medicine company said it has appointed Professor Jo Neill as chair of the Clinical Advisory Board and Parminder Singh to head the Scientific Advisory Board.

“We are delighted to have such authority with Jo and Parminder, they bring a wealth of knowledge and expertise in each of their disciplines and we look forward to working with them in driving our Clinical and Scientific Advisory boards,” said Graeme McFarlane, the company’s chief commercial officer.

READ: Albert Labs announces C$4M financing ahead of CSE listing

Albert Labs leverages Real-World Evidence (RWE) studies across Europe to accelerate access to its proprietary psilocybin-based therapy for patients with urgent, unmet mental health needs.

The company noted that Neill is a professor of psychopharmacology at the University of Manchester (Division of Pharmacy & Optometry). She is also chair of the Medical Psychedelics Working Group for Drug Science, a scientific advisor for Heroic Hearts UK.

Singh, it said, is a seasoned executive with more than 30 years of technical, operations, international business, and management experience in both corporate and entrepreneurial environments. His previous experience includes his role as CEO of LifeLens Technologies, an innovation company.

For their new roles, Albert Labs said Neill will help guide decisions on the running of the RWE trials program, while Singh and the Scientific Advisory Board will work directly with the company’s laboratory team and be responsible for IP protection and development of novel manufacturing technologies through natural cultivation, extraction, formulation, and delivery.

The company said it expects to announce completely staffed boards with additional expertise in psychology, psychiatry, palliative care, and oncology as well as mycology and medicinal plant licencing and compliance.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *